RSS
PTLA

Rosenblum Silverman Sutton’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Rosenblum Silverman Sutton’s Portfolio PTLA Stock Details PTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-23,665
Closed -$1.32M – 67
2018
Q4 		$1.32M Sell
23,665
-124,705
-84% -$2.56M 0.6% 39
2018
Q3 		$3.95M Sell
148,370
-10,640
-7% -$347K 1.31% 28
2018
Q2 		$6.01M Buy
159,010
+33,800
+27% +$1.29M 2.08% 16
2018
Q1 		$4.09M Sell
125,210
-3,250
-3% -$143K 1.45% 27
2017
Q4 		$6.25M Sell
128,460
-870
-0.7% -$44K 2.25% 16
2017
Q3 		$6.99M Buy
129,330
+22,710
+21% +$1.33M 2.65% 13
2017
Q2 		$5.99M Buy
106,620
+7,835
+8% +$314K 2.39% 13
2017
Q1 		$3.87M Buy
+98,785
New +$3.15M 1.64% 26

Other funds holding PTLA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Rosenblum Silverman Sutton's PTLA Position: Q1 2019 in Review

Rosenblum Silverman Sutton sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q1 2019, closing a stake of 23,665 shares — an estimated $1.32M sold.

Rosenblum Silverman Sutton first reported a position in PTLA in Q1 2017 and held it in 8 quarters. The position peaked at $6.99M in Q3 2017. 209 funds tracked by Wall St. Rank hold PTLA as of Q1 2019.

  • Rosenblum Silverman Sutton reported no remaining Portola Pharmaceuticals, Inc. position as of Q1 2019 after selling out during the quarter.
  • Rosenblum Silverman Sutton sold 23,665 Portola Pharmaceuticals, Inc. shares in Q1 2019, an estimated $1.32M.
  • Rosenblum Silverman Sutton first reported a position in Portola Pharmaceuticals, Inc. in Q1 2017 and held it in 8 quarters.
  • Rosenblum Silverman Sutton's Portola Pharmaceuticals, Inc. position peaked at $6.99M in Q3 2017.
  • 209 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q1 2019.

Based on Rosenblum Silverman Sutton's 13F filing for Q1 2019, filed 25 Apr 2019.